Clinical Developments in Diabetes
Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you from the annual American Diabetes Association meeting in Chicago, Illinois. I would like to summarize the abstracts that I have found interesting — not everything of note, but the abstracts that I believe are clinically the most important.
A few of these are new developments, the first of which is the artificial pancreas. Everyone likes the idea of the artificial pancreas, even if the reality is still years away. I will also discuss some of the new drugs and combination drugs that incorporate different types of long-acting insulindifferent types of glucagon-like peptide 1 (GLP-1) receptor agonists, and the newest class of drugs, the sodium glucose co-transporter 2 (SGLT2) inhibitors. Those are the areas which have seen the most movement in the field in terms of new data and new ideas for treating our patients.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: Top Picks From ADA - Medscape - Jul 11, 2013.
How to Reduce Renal Risk in Type 2 Diabetes
Change Makers: Dr Cheryl Pegus on How Walmart Is Rethinking Health
Hybrid ACC.22 Resurrects the Live Scientific Session
COMMENTARY
Top Picks From ADA
Anne L. Peters, MD, CDE
DisclosuresJuly 11, 2013
Clinical Developments in Diabetes
Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you from the annual American Diabetes Association meeting in Chicago, Illinois. I would like to summarize the abstracts that I have found interesting — not everything of note, but the abstracts that I believe are clinically the most important.
A few of these are new developments, the first of which is the artificial pancreas. Everyone likes the idea of the artificial pancreas, even if the reality is still years away. I will also discuss some of the new drugs and combination drugs that incorporate different types of long-acting insulindifferent types of glucagon-like peptide 1 (GLP-1) receptor agonists, and the newest class of drugs, the sodium glucose co-transporter 2 (SGLT2) inhibitors. Those are the areas which have seen the most movement in the field in terms of new data and new ideas for treating our patients.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: Top Picks From ADA - Medscape - Jul 11, 2013.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author
Anne L. Peters, MD, CDE
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, CDE, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk.
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis